H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oncternal Therapeutics (ONCT – Research Report) today and set a price target of $9.00. The company's shares closed last Monday at $2.56, close to its 52-week low of $2.54. According to TipRanks.com, Selvaraju 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -16.7% and a 21.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Inovio Pharmaceuticals, and Vallon Pharmaceuticals. Currently, the analyst consensus on Oncternal Therapeutics is a Moderate Buy with an average price target of $9.00.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-oncternal-therapeutics-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral